TRIP13

Across TCGA pan-cancer cohorts, TRIP13 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TRIP13’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TRIP13 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRIP13 is over-expressed in tumor.

CCRCC, HNSC, and COAD are the cancer types where TRIP13 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIP13 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+1.869	<.001	12	view →
HNSC	All	All	+0.907	<.001	12	view →
COAD	Female	All	+0.877	<.001	12	view →
LSCC	Female	II,III,IV	+1.694	<.001	9	view →
LUAD	Male	All	+0.622	<.001	8	view →
PDAC	All	All	+0.631	<.001	7	view →
OV	All	All	+0.473	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TRIP13–CCRCC

Open the CCRCC breakdown →